Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.
Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).
Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.
Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.
History of tuberculosis , presence of active tuberculosis, or latent tuberculosis
Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).
Active malignancy or history of malignancy.
Other protocol defined exclusion criteria could apply.

NCT03364036_exc_T1
Temporal
Previous
NCT03364036_exc_T2
Drug
drugs
NCT03364036_exc_T3
Drug
fingolimod
NCT03364036_exc_T4
Drug
natalizumab
NCT03364036_exc_T5
Drug
alemtuzumab
NCT03364036_exc_T6
Drug
mitoxantrone
NCT03364036_exc_T7
Drug
ocrelizumab
NCT03364036_exc_T8
Scope
fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab
NCT03364036_exc_T9
Value
Positive
NCT03364036_exc_T10
Measurement
epatitis C urface antigen test
NCT03364036_exc_T11
Measurement
hepatitis B surface antigen test
NCT03364036_exc_T12
Measurement
hepatits B core antibody test
NCT03364036_exc_T13
Qualifier
immunoglobulin G (IgG)
NCT03364036_exc_T14
Qualifier
immunoglobulin M (IgM)
NCT03364036_exc_T15
Scope
immunoglobulin G (IgG) and/or immunoglobulin M (IgM)
NCT03364036_exc_T16
Scope
hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM)
NCT03364036_exc_T17
Temporal
Current
NCT03364036_exc_T18
Temporal
previous history
NCT03364036_exc_T20
Condition
immune deficiency disorders
NCT03364036_exc_T21
Measurement
human immunodeficiency virus (HIV)
NCT03364036_exc_T22
Value
positive
NCT03364036_exc_T19
Scope
Current or previous history
NCT03364036_exc_T23
Procedure
unosuppressive or rapy wi
NCT03364036_exc_T24
Procedure
myelosuppressive therapy
NCT03364036_exc_T25
Temporal
Currently
NCT03364036_exc_T26
Drug
monoclonal antibodies
NCT03364036_exc_T27
Drug
methotrexate
NCT03364036_exc_T28
Drug
cyclophosphamide
NCT03364036_exc_T29
Drug
cyclosporine
NCT03364036_exc_T30
Drug
azathioprine
NCT03364036_exc_T31
Drug
corticosteroids
NCT03364036_exc_T32
Multiplier
chronic use
NCT03364036_exc_T33
Scope
monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids
NCT03364036_exc_T34
Scope
immunosuppressive or myelosuppressive therapy
NCT03364036_exc_T35
Procedure
tuberculosis
NCT03364036_exc_T36
Procedure
tuberculosis
NCT03364036_exc_T37
Procedure
tuberculosis
NCT03364036_exc_T38
Qualifier
latent
NCT03364036_exc_T39
Qualifier
active
NCT03364036_exc_T40
Observation
History
NCT03364036_exc_T41
Condition
Progressive Multifocal Leukoencephalopathy (PML)
NCT03364036_exc_T42
Procedure
Magnetic Resonance Imaging (MRI)
NCT03364036_exc_T43
Mood
Evidence
NCT03364036_exc_T44
Mood
suspect
NCT03364036_exc_T45
Scope
Evidence or suspect
NCT03364036_exc_T46
Observation
history
NCT03364036_exc_T47
Condition
malignancy
NCT03364036_exc_T48
Condition
malignancy
NCT03364036_exc_T49
Qualifier
Active